Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track XLO with free AI briefings, catalyst countdowns, and dilution alerts.

XLO · Xilio Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$122.2M Cash on Hand
22.5mo Cash Runway
Follow XLO by email Get an email when XLO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XLO, unsubscribe in one click. Privacy

📣 What XLO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vilastobart Advanced Solid Tumor Phase 1/2 · NCT04896697 Completed
Protein-engineered Interleukin-2 XTX202 Advanced Solid Tumor Phase 1/2 · NCT05052268 Completed
Protein-engineered Interleukin-12 XTX301 Advanced Solid Tumor Phase 1/2 · NCT05684965 Recruiting

Also used in these trials (approved or third-party drugs, not XLO's own candidates): Atezolizumab, Retifanlimab, Tumor Protease-activated Anti-PD-1/IL-2 Fusion Protein XTX501.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XLO holds $122.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.3M/quarter from operations, an estimated runway of 22.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 28 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XLO files for a raise →

👥 Who Owns XLO

Insiders 5.7% Other 5%+ holders 94.3% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
GILEAD SCIENCES, INC. 5%+ holder (13G) 14,517,678 205.52% 2025-12-31
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 4,676,472 66.20% 2025-12-31
Sirenia Capital Management LP Institution (13G, 5%+) 1,142,862 16.18% 2026-03-31
Coastlands Capital LP Institution (13G, 5%+) 731,573 10.36% 2026-09-30
BCLS II Equity Opportunities, LP 5%+ holder (13G) 664,021 9.40% 2026-03-31
ORBIMED ADVISORS LLC Institution (13G, 5%+) 642,000 9.09% 2026-03-31
StemPoint Capital LP Institution (13G, 5%+) 628,866 8.90% 2026-06-30
Adage Capital Management, L.P. Institution (13G, 5%+) 464,598 6.58% 2026-09-30
Rene Russo
PRESIDENT AND CEO, Director · +3.98M options
Insider 325,422 4.61% 2025-12-31
Katarina Luptakova
CHIEF MEDICAL OFFICER · +910,345 options
Insider 33,250 0.47% 2025-12-31
Christopher James Frankenfield
Chief Financial Officer · +1.88M options
Insider 24,766 0.35% 2025-12-31
James Samuel Shannon
Director · +36,000 options
Insider 10,000 0.14% 2026-03-26

Share count 7,063,982 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full XLO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XLO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.